+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 55Years +
All Genders
ID07602582

Evaluating Annual Intravenous Donanemab in Adults Who Completed AACM Study for Alzheimer Disease

Led by Eli Lilly and Company · Updated on 2026-10-28

550

Participants Needed

62

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate whether participants who have previously taken donanemab experience clinical benefits when receiving annual doses. The study focuses on individuals with Alzheimer disease, dementia, and amyloid plaque conditions, investigating the effects of continued treatment over a period of up to 2.5 years with six visits. The trial is sponsored by Eli Lilly and Company and is conducted as a randomized, double-blind, phase 3 clinical trial. Participants are assigned to receive either donanemab or a placebo, both administered intravenously. The study follows a parallel design where each participant receives one of the two treatments. The annual dosing schedule spans up to 2.5 years, with visits planned throughout this period to monitor participants. This includes assessments of cognitive function, brain amyloid plaque levels via PET scans, plasma biomarkers, and drug concentration measurements. During the study, participants will undergo evaluations including the Clinical Dementia Rating - Sum of Boxes CDR-SB, Cognitive Function Index CFI, Florbetapir F 18 PET scans, and plasma phosphorylated tau measurements. Pharmacokinetics of donanemab will be assessed at baseline, week 52, and week 104. The study involves six visits over the entire duration, with safety and clinical benefit monitored carefully. Participation lasts up to 2.5 years, allowing comprehensive observation of treatment effects.

CONDITIONS

Brief Title

A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

Research Team

T

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

P

Physicians interested in becoming principal investigators please contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here